Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Authors: Conlon, Neil T, Roche, Sandra, Mahdi, Amira F, Browne, Alacoque, Breen, Laura, Gaubatz, Johanna, Meiller, Justine, O'Neill, Fiona, O'Driscoll, Lorraine, Cremona, Mattia, Hennessy, Bryan T, Eli, Lisa D, Crown, John, Collins, Denis M

Source: In Translational Oncology November 2024 49

Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial

Authors: Friedman, Claire F., D'Souza, Anishka, Bello Roufai, Diana, Tinker, Anna V., de Miguel, Maria, Gambardella, Valentina, Goldman, Jonathan, Loi, Sherene, Melisko, Michelle E., Oaknin, Ana, Spanggaard, Iben, Shapiro, Geoffrey I., ElNaggar, Adam C., Panni, Stefano, Ravichandran, Vignesh, Frazier, Aimee L., DiPrimeo, Daniel, Eli, Lisa D., Solit, David B.

Source: In Gynecologic Oncology February 2024 181:162-169

Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial

Authors: Goldman, Jonathan W. ^{1, ⁎}, Bueno, Alejandro Martinez ², Dooms, Christophe ³, Jhaveri, Komal ⁴, de Miguel, Maria ⁵, Piha-Paul, Sarina A. ⁶, Unni, Nisha ⁷, Zick, Aviad ⁸, Mahipal, Amit ⁹, Suga, J. Marie ¹⁰, Naltet, Charles ¹¹, Antoñanzas, Monica ¹², Crown, John ¹³, Bebchuk, Judith ¹⁴, Eli, Lisa D. ¹⁴, Lowenthal, Beth H. ¹⁴, Mahalingam, Devalingam ¹⁵

Source: In Clinical Lung Cancer December 2024

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Authors: Oaknin, Ana, Friedman, Claire F., Roman, Lynda D., D'Souza, Anishka, Brana, Irene, Bidard, François-Clement, Goldman, Jonathan, Alvarez, Edwin A., Boni, Valentina, ElNaggar, Adam C., Passalacqua, Rodolfo, Do, Khanh T.M., Santin, Alessandro D., Keyvanjah, Kiana, Xu, Feng, Eli, Lisa D., Lalani, Alshad S., Bryce, Richard P., Hyman, David M., Meric-Bernstam, Funda, Solit, David B., Monk, Bradley J.

Source: In Gynecologic Oncology October 2020 159(1):150-156

Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma

Authors: Abou-Alfa, Ghassan K., Meyer, Tim, Do, Richard Kinh Gian, Piha-Paul, Sarina A., Light, Joseph S., Sherrin, Scott, Yaqubie, Amin, O’Neill, Alison Clemens, Harding, James J., Al-Rajabi, Raed, Denlinger, Crystal S., Cano, Pablo, Cornelius, Albert S., O'Reilly, Eileen M., DiPrimeo, Daniel, Eli, Lisa D., Gordan, John D., Solit, David B.

Source: Liver Cancer; May 2024, Vol. 14 Issue: 1 p58-67, 10p

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Authors: Chia, Stephen K. L., Martin, Miguel, Holmes, Frankie A., Ejlertsen, Bent, Delaloge, Suzette, Moy, Beverly, Iwata, Hiroji, von Minckwitz, Gunter, Mansi, Janine, Barrios, Carlos H., Gnant, Michael, Tomašević, Zorica, Denduluri, Neelima, Šeparović, Robert, Kim, Sung-Bae, Jakobsen, Erik Hugger, Harvey, Vernon, Robert, Nicholas, Smith, John, Harker, Graydon, Zhang, Bo, Eli, Lisa D., Ye, Yining, Lalani, Alshad S., Buyse, Marc, Chan, Arlene

Source: Breast cancer research. 21(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100129319437.0x000001&indx=1&recIds=ETOCvdc_100129319437.0x000001

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitroand in vivo

Authors: Conlon, Neil T, Roche, Sandra, Mahdi, Amira F, Browne, Alacoque, Breen, Laura, Gaubatz, Johanna, Meiller, Justine, O'Neill, Fiona, O'Driscoll, Lorraine, Cremona, Mattia, Hennessy, Bryan T, Eli, Lisa D, Crown, John, Collins, Denis M

Source: Translational Oncology; November 2024, Vol. 49 Issue: 1

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.

Authors: Conlon, Neil T., Kooijman, Jeffrey J., van Gerwen, Suzanne J. C., Mulder, Winfried R., Zaman, Guido J. R., Diala, Irmina, Eli, Lisa D., Lalani, Alshad S., Crown, John, Collins, Denis M.

Source: British Journal of Cancer; Mar2021, Vol. 124 Issue 7, p1249-1259, 11p

Subject Terms: QUINOLINE, CANCER cell culture, RESEARCH, PROTEIN kinase inhibitors, RESEARCH methodology, CELL receptors, CELL physiology, APOPTOSIS, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, GENES, RESEARCH funding, TUMORS, PHARMACODYNAMICS

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.

Authors: Lee, Jangsoon, Liu, Huey, Pearson, Troy, Iwase, Toshiaki, Fuson, Jon, Lalani, Alshad S., Eli, Lisa D., Diala, Irmina, Tripathy, Debu, Lim, Bora, Ueno, Naoto T.

Source: Biomedicines; Jul2021, Vol. 9 Issue 7, p740, 1p

Subject Terms: HER2 positive breast cancer, EVEROLIMUS, TRIPLE-negative breast cancer, BREAST cancer, EPIDERMAL growth factor receptors, PHOSPHATIDYLINOSITOL 3-kinases

This result is not displayed to guests.
Login for full access.

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.

Authors: Collins, Denis M., Conlon, Neil T., Kannan, Srinivasaraghavan, Verma, Chandra S., Eli, Lisa D., Lalani, Alshad S., Crown, John

Source: Cancers; Jun2019, Vol. 11 Issue 6, p737, 1p

Subject Terms: PROTEIN-tyrosine kinase inhibitors, TRASTUZUMAB, HETEROCYCLIC compounds, CELL receptors, EPIDERMAL growth factor, AROMATASE inhibitors, THERAPEUTIC use of antimetabolites, BREAST tumors, COMBINATION drug therapy, COMBINED modality therapy, METASTASIS, GENETIC mutation, TUMOR classification, DRUG approval, SYMPTOMS, THERAPEUTICS

Geographic Terms: EUROPE, UNITED States

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Authors: Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, Solit, David B.

Source: Nature; February 2019, Vol. 566 Issue: 7745 pE11-E12, 2p